WO2014104162A1 - Médicament - Google Patents

Médicament Download PDF

Info

Publication number
WO2014104162A1
WO2014104162A1 PCT/JP2013/084803 JP2013084803W WO2014104162A1 WO 2014104162 A1 WO2014104162 A1 WO 2014104162A1 JP 2013084803 W JP2013084803 W JP 2013084803W WO 2014104162 A1 WO2014104162 A1 WO 2014104162A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
blood flow
toki
component
present
Prior art date
Application number
PCT/JP2013/084803
Other languages
English (en)
Japanese (ja)
Inventor
宣彦 福岡
朋彦 中田
Original Assignee
興和株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 興和株式会社 filed Critical 興和株式会社
Priority to JP2014554528A priority Critical patent/JPWO2014104162A1/ja
Publication of WO2014104162A1 publication Critical patent/WO2014104162A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to a medicine having a recovery action against fatigue.
  • Fatigue is defined as a “temporary state of reduced functional ability resulting from physical or mental activity”, which not only reduces QOL but also causes a decrease in immunity. Since it may lead to diseases and the like, there is a long-awaited demand for providing a medicine having an excellent fatigue recovery action.
  • Patent Document 1 it is known that touki and ogi have an effect of improving peripheral circulation.
  • Patent Document 1 the combination of these, the blood flow promoting action, the fatigue recovery action and the like by the combination have not been studied so far.
  • An object of the present invention is to provide a new medicine having a recovery action against fatigue.
  • the present inventors consider that improvement of blood circulation is important in eliminating the accumulation of fatigue substances and activating energy metabolism in providing a new medicine having a recovery action against fatigue, and particularly promoting blood flow.
  • the combination of Toki or its extract, Ezokogi or its extract, and Ogi or its extract exhibits a synergistic blood flow promoting action, and has an excellent fatigue recovery action.
  • the present invention provides the following components (A) to (C): (A) Toki or its extract; (B) Ezoukogi or an extract thereof; (C) Ogi or its extract;
  • the present invention provides a medicine for recovering fatigue, which is a combination of the above.
  • the present invention also includes the following components (A) to (D): (A) Toki or its extract; (B) Ezoukogi or an extract thereof; (C) Ogi or its extract; (D) garlic or an extract thereof;
  • the present invention provides a medicine for recovering fatigue, which is a combination of the above.
  • the present invention also includes the following components (A) to (C): (A) Toki or its extract; (B) Ezoukogi or an extract thereof; (C) Ogi or its extract; It is intended to provide a blood flow promoter.
  • the present invention also includes the following components (A) and (D): (A) Toki or its extract; (D) garlic or an extract thereof; It is intended to provide a blood flow promoter.
  • the present invention provides the following components (A) to (D): (A) Toki or its extract; (B) Ezoukogi or an extract thereof; (C) Ogi or its extract; (D) garlic or an extract thereof; It is intended to provide a blood flow promoter.
  • the medicament for recovery from fatigue according to the present invention exhibits an excellent blood flow promoting action and fatigue recovery action and is useful as a medicament for the purpose of nutrition tonic and the like.
  • the blood flow promoting agent according to the present invention is useful as a medicament for the purpose of alleviating various symptoms due to peripheral blood circulation disorders based on an excellent blood flow promoting action.
  • the present invention is a medicine for recovery from fatigue, which is either Toki or an extract thereof (hereinafter also referred to as “component (A)”) and Ezokogi or an extract thereof (hereinafter also referred to as “component (B)”). ) And an extract of ogi or an extract thereof (hereinafter also referred to as “component (C)”) (hereinafter referred to herein as the medicament for recovery from fatigue of the present invention, particularly “ Also referred to as “medicine of the present invention.”
  • component (A) an extract thereof
  • component (B) Ezokogi or an extract thereof
  • component (C) an extract of ogi or an extract thereof
  • medicine of the present invention is a concept that encompasses quasi-drugs in addition to pharmaceutical products.
  • the medicament of the present invention is a medicament for recovery from fatigue, and administers the component (A), the component (B), and the component (C) simultaneously or at different times.
  • the combination of the component (A), the component (B), and the component (C) exhibits a synergistically enhanced excellent blood flow promoting action. It exerts excellent fatigue recovery action by eliminating accumulation of fatigue substances and activating energy metabolism through the promoting action.
  • the components (A) to (C) are preferably administered simultaneously from the viewpoint of blood flow promoting action and fatigue recovery action.
  • component (D) garlic or an extract thereof (hereinafter also referred to as “component (D)”) is combined. More preferred. As apparent from Test Examples 2 and 3 below, the combination of the component (A) and the component (D) exhibits a synergistically enhanced excellent blood flow promoting action, so that the component (A) and the component ( By combining component (D) in addition to the combination of B) and component (C), the blood flow promoting effect and the fatigue recovery effect are further improved. In combination with component (D), it may be administered at the same time as component (A), component (B) or component (C), or may be administered at different times. From the viewpoint of fatigue recovery action, the components (A) to (D) are preferably administered simultaneously.
  • the medicament of the present invention is provided as a unit dosage form combination (kit) containing each of the above components separately, or as a unit dosage form pharmaceutical composition containing all of the components together.
  • kit unit dosage form combination
  • pharmaceutical composition is provided in a unit dosage form containing all components together.
  • Touki means the roots of Toki (Angelica actiloba Kitagawa) or Hokaitouki (Angelica acutiloba Kitagawa var. Sugiyamae Hikino (Umbelliferae)), as described in the 16th revision Japanese Pharmacopoeia.
  • the shape of the touki can be adjusted as necessary, and can be cut or crushed into small pieces, small chunks, or pulverized into powder.
  • “toki powder” made from toki powder is also used in the present invention. Can do.
  • the one obtained by performing some kind of extraction treatment on the touki may be used.
  • extract of touki includes those subjected to processing such as heating, drying and pulverization in addition to extraction processing. Specifically, after adjusting the size of the touki as appropriate, a leached solution (extraction solvent) added to the leached solution, a concentrated solution of the leached solution (soft extract, tincture, etc.), and these A dried product (dried extract or the like) is also included in the “extract of Toki” of the present invention.
  • dried toki is preferable.
  • the method for producing the extract of Toki is not particularly limited.
  • the description of the “Extract”, “Dipping / decoction”, “Tinki”, “Ryu Extract” in the 16th revised Japanese Pharmacopoeia It can be produced with reference to known methods for producing plant extracts. Specifically, for example, it can be produced by cutting, heating, drying, pulverizing, or the like, if necessary, and then performing extraction by adding an appropriate extraction solvent. The obtained extract may be further concentrated, dried, etc. as necessary.
  • the extraction solvent examples include lower monohydric alcohols such as methanol, ethanol, isopropanol, and n-butanol; lower polyhydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, and glycerin; ethers such as diethyl ether.
  • Ketones such as acetone and ethyl methyl ketone; esters such as ethyl acetate; nitriles such as acetonitrile; alkanes such as pentane, hexane, cyclopentane and cyclohexane; halogenoalkanes such as dichloromethane and chloroform; benzene, toluene and the like Aromatic hydrocarbons; dimethylformamide; dimethylsulfoxide; water (including hot water) and the like. These may be used alone or in combination of two or more. In the present invention, water, ethanol, or a mixture of water and ethanol is preferred.
  • the extraction operation is not particularly limited, and a known method used for the extraction operation from plants can be adopted. Specifically, for example, immersion in extraction solvent (cooling, digestion, percolation, etc.), super For example, extraction using a critical fluid or a subcritical fluid may be mentioned. In addition, in order to raise extraction efficiency, you may homogenize in stirring or an extraction solvent.
  • the extraction temperature is not particularly limited and varies depending on the extraction solvent to be used, the extraction operation, and the like, but is preferably set to a temperature from about 5 ° C. to the boiling point of the extraction solvent.
  • the extraction time is not particularly limited and varies depending on the extraction solvent to be used, the extraction operation, etc., but is preferably about 1 hour to 14 days.
  • commercially available products can be used as Touki or an extract thereof, and specific examples of commercially available products include Toki-style extract and dried Toki extract (above, manufactured by Koshiro Pharmaceutical Co., Ltd.).
  • Ezoukogi is a deciduous shrub belonging to the family Araceae that originates in Russia, China (Heilongjiang basin) and Japan (eastern Hokkaido), and its scientific name is Eleutherococcus senticosus. Ezokogi is also called Sashigoka. In the present invention, all or a part (for example, roots, trunks, bark, branches, leaves, flowers, seeds, seed coats, etc.) constituting the sorghum can be used. Ezoukogi can be adjusted as needed.
  • the extract of elephant in consideration of the convenience of handling at the time of production of a pharmaceutical, etc., it is also possible to use a product obtained by performing some kind of extraction treatment on the elephant (hereinafter referred to as “the extract of elephant”).
  • the above-mentioned “Ezocogi extract” includes those subjected to processing such as heating, drying and pulverization in addition to extraction processing. Specifically, after adjusting the size of the elephant to an appropriate size, an appropriate leachate (extraction solvent) is added to the leachate, and the leachate is concentrated (soft extract, tincture, etc.). A dried product (dried extract or the like) is also included in the “Erucogi extract” of the present invention. In the present invention, the dried sorghum extract is preferred as the sorghum or extract thereof.
  • the method for producing the extract of Ezoukogi is not particularly limited, and for example, it can be produced by the same method as the method for producing the extract of Toki.
  • Ezoukogi or its extract examples include Ezocogi extract-A, Ezocogi extract-S, Ezocogi-style extract, Eleuterococcus dry extract (above, Japan). Powdered chemicals).
  • the ratio of the combination of Toki or its extract and Ezokogi or its extract in the medicament of the present invention is not particularly limited, but from the viewpoint of blood flow promoting action and fatigue recovery action, Toki or its extract is converted into a crude drug equivalent of Toki.
  • a ratio of 0.01 to 100 parts by weight, more preferably 0.1 to 10 parts by weight, and particularly preferably 1 to 5 parts by weight, in terms of the amount of the raw drug of sorghum, based on 1 part by weight Are preferably combined.
  • ⁇ Ingredient (C)> “Ougi” (yellow jade) means the root of Astragalus membranaceus Bunge or Astragalus mongholicus Bunge (Leguminosae) as described in the 16th revision Japanese Pharmacopoeia. Ogi can adjust its form as needed.
  • a product obtained by subjecting a parrot to some kind of extraction treatment hereinafter referred to as an “parrot extract” may be used.
  • the “seed extract” includes those subjected to processing such as heating, drying, and pulverization.
  • an appropriate leaching solution extraction solvent
  • the leaching solution is concentrated (soft extract, tincture, etc.).
  • a dried product is also included in the “extract of ogi” of the present invention.
  • dried ogi is preferred as the ogi or its extract.
  • the method for producing the extract of ogi is not particularly limited, and can be produced, for example, by the same method as the method for producing the extract of touki.
  • a commercially available product can be used as the ogi or an extract thereof.
  • Specific examples of commercially available products include ogi extract, ogi-style extract, ogi-style extract-C, and jaundice dry extract (above, Japanese powder). Yakuhin Co., Ltd.).
  • the combination ratio of the touki or extract thereof and the ogi or extract thereof in the medicament of the present invention is not particularly limited, but from the viewpoint of blood flow promoting action and fatigue recovery action, the toki or extract thereof is converted into a raw drug equivalent of toki.
  • a ratio of 0.01 to 100 parts by weight, more preferably 0.1 to 10 parts by weight, particularly preferably 1 to 5 parts by weight, in terms of the raw drug substance of the ogi, relative to 1 part by weight Are preferably combined.
  • Garlic (Daiseng) means the bulb of garlic (Allium sativum). Garlic can adjust its form as needed.
  • garlic that has been subjected to some extraction process (hereinafter referred to as “garlic extract”) may be used.
  • the “garlic extract” includes those subjected to processing such as heating, drying, and pulverization in addition to extraction processing. Specifically, after garlic is appropriately sized as necessary, a leaching solution (extraction solvent) is added and leached, a concentration of the leaching solution (soft extract, tincture, etc.), A dried product (dried extract or the like) is also included in the “garlic extract” of the present invention.
  • garlic or an extract thereof is preferably processed potato (garlic powder or extract prepared by subjecting a heat-treated garlic extract to a lower alcohol extraction or the like).
  • the method for producing the garlic extract is not particularly limited, and for example, the garlic extract can be produced by the same method as the method for producing the extract of Toki.
  • commercially available products can be used as garlic or an extract thereof.
  • Specific examples of commercially available products include garlic extract (manufactured by Alps Pharmaceutical Co., Ltd.), garlic extract (manufactured by Nippon Powder Chemical Co., Ltd.). ), Oxoamidin powder, oxoresin powder, oxoresin powder (made by Riken Chemical Industry Co., Ltd.) and the like.
  • the combination ratio of the touki or extract thereof and the garlic or extract thereof in the medicament of the present invention is not particularly limited, from the viewpoint of blood flow promoting action and fatigue recovery action, the toki or extract thereof is converted to the toki drug substance.
  • the amount of garlic or an extract thereof is 0.01 to 10 parts by mass, more preferably 0.05 to 5 parts by mass, particularly preferably 0.1 to 1 part by mass in terms of the garlic drug substance based on 1 part by mass. It is preferable to combine at a ratio of In the present invention, when processed potatoes are used as garlic or an extract thereof, 0.01 to 10 parts by mass of processed potatoes are obtained with respect to 1 part by mass of Toki or its extract in terms of the crude drug equivalent of Toki. A combination of 0.05 to 5 parts by mass, particularly preferably 0.1 to 1 part by mass is preferable.
  • the medicament of the present invention may be either a medicament suitable for oral administration or a medicament suitable for parenteral administration.
  • a pharmaceutical suitable for oral administration is a solid or semi-solid form comprising component (A), component (B), component (C), and preferably further component (D) in one unit dosage form.
  • component (A), component (B), component (C), and preferably further component (D) in one unit dosage form is more preferable that it is provided as a liquid pharmaceutical composition.
  • dosage form in providing the medicament of the present invention as a medicament suitable for oral administration or a medicament suitable for parenteral administration
  • its administration form is not particularly limited.
  • dosage forms include pharmaceutical compositions in solid form such as powders, granules, tablets, chewable tablets, film-coated tablets, dragees, soft capsules, hard capsules, etc .; in the form of solutions such as drinks Pharmaceutical composition; Pharmaceutical composition in semi-solid form such as jelly agent.
  • the pharmaceutical composition is in a solid form from the viewpoint of ease of administration.
  • each of the components in the pharmaceutical composition is not particularly limited, and is determined according to the form of the pharmaceutical composition, taking into account the combination ratio as appropriate.
  • the component (A) is 0.1 to 20% by mass (preferably 0.5 to 15% by mass, particularly preferable) with respect to the total mass of the pharmaceutical composition.
  • component (B) preferably 0.1 to 10% by mass, particularly preferably 0.5 to 5% by mass
  • component (C) 0.1 to 20% by weight (preferably 0.5 to 15% by weight, particularly preferably 1 to 10% by weight)
  • component (D) 1 to 25% by weight (preferably 3 to 20% by weight)
  • the content is preferably 5 to 15% by mass).
  • components other than the above (A) to (D) can be appropriately blended depending on the purpose.
  • examples of such components include retinols (retinol acetate, retinol palmitate, vitamin A oil, etc.), liver oils (liver oil, strong liver oil, etc.), vitamin Ds (ergocalciferol, cholecalciferol, etc.), vitamins, and the like.
  • Class E (d- ⁇ -tocopherol succinate, dl- ⁇ -tocopherol succinate, dl- ⁇ -tocopherol calcium succinate, d- ⁇ -tocopherol acetate, dl- ⁇ -tocopherol acetate, d- ⁇ -tocopherol, dl- ⁇ -tocopherol, etc.), vitamin B1 (thiamine hydrochloride, thiamine nitrate, bisthiamine nitrate, thiamine disulfide, thiamine dicetyl sulfate ester, dicetiamine hydrochloride, fursultiamine hydrochloride, octothiamine, chicotiamine, bisbutiamine, bisbenchamine, Furusuchi Min, prosultiamine, benfotiamine, etc.), vitamin B2 (such as flavin adenine dinucleotide sodium, riboflavin, riboflavin sodium phosphate, riboflavin butyrate),
  • the medicament of the present invention can be appropriately produced by a technique commonly used in the art.
  • one or more kinds of pharmaceutical additives usually used in the art may be used as necessary depending on the specific dosage form.
  • pharmaceutical additives include, but are not limited to, excipients, binders, disintegrants, lubricants, colorants, corrigents, and coating agents.
  • Excipients include lactose, starches, crystalline cellulose, sucrose, mannitol, light anhydrous silicic acid and the like.
  • binder include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like.
  • disintegrant include sodium carboxymethyl starch, carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose.
  • the lubricant include magnesium stearate and talc.
  • colorant include tar pigments and iron sesquioxide.
  • Examples of the corrigent include stevia, aspartame, and fragrances.
  • Coating agents include film-forming polymers such as carboxymethyl ethyl cellulose, cellulose acetate phthalate, methacrylic acid copolymer S, methacrylic acid copolymer L, methacrylic acid copolymer LD, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate.
  • film-forming polymers such as carboxymethyl ethyl cellulose, cellulose acetate phthalate, methacrylic acid copolymer S, methacrylic acid copolymer L, methacrylic acid copolymer LD, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate.
  • plasticizers such as triethyl citrate, triacetin and polyethylene glycol, talc, titanium oxide, yellow ferric oxide, ferric oxide, legal dye, light anhydrous silicic acid
  • the dose of the medicament of the present invention is not particularly limited, and can be appropriately selected according to various conditions such as the form of the medicament, the degree of symptoms to be applied, and the age of the patient. In normal cases, adults should be administered about 10 to 1000 mg / day, in particular about 50 to 200 mg / day, of the sugar beet equivalent or extract thereof, depending on the dose.
  • the dosage of the components can be determined.
  • the method for administering the medicament of the present invention is not particularly limited, and each component can be administered simultaneously or at different times. When these components are administered at different times, it is desirable to administer other components within a time when the blood concentration of the previously administered component does not decrease. In the present invention, it is preferable to administer these components at the same time from the viewpoint of blood flow promoting action and fatigue recovery action.
  • the medicament of the present invention has an excellent blood flow promoting action, and as described in Test Example 3 below, by eliminating the accumulation of fatigue substances and activating energy metabolism through such blood flow promoting action, Excellent fatigue recovery action. Therefore, the medicament of the present invention can be used to relieve symptoms such as eye strain, muscle fatigue, low back pain, stiff shoulders, general malaise, or tonic, nutritional supplementation (for example, physical fatigue, decreased physical fitness after illness, loss of appetite, nutritional disorder) ⁇ It can be used as a medicine for the enhancement of physical fitness)
  • the present invention also provides the following blood flow promoters 1) to 3). 1) A blood flow promoter comprising a combination of component (A), component (B) and component (C); 2) A blood flow promoter comprising a combination of component (A) and component (D); 3) A blood flow promoter comprising a combination of component (A), component (B), component (C) and component (D); As will be apparent from Test Examples 1 and 2 below, the above combination exhibits a synergistically enhanced excellent blood flow promoting action.
  • the blood flow promoting agent of the present invention can be used as a medicament for alleviating various symptoms (strain of shoulders / neck streaks, numbness of hands and feet, coldness, temperance) due to peripheral blood circulation disorders based on such blood flow promoting action. .
  • the meaning of each word, the amount of each component used, the production method, and the like are the same as in the case of the above-mentioned pharmaceutical for recovery from fatigue.
  • the blood flow value When the blood flow value was stabilized, the blood flow was recorded as a Pre value. Thereafter, physiological saline (control) or a test drug was administered from the jugular vein, and the maximum value of blood flow for 2 minutes after drug administration was recorded as the Post value.
  • the average of the blood flow increase rate of each test drug administration group By dividing the value by the average value of the blood flow rate increase rate of the control, the relative value (rate relative to the control) of the blood flow rate increase rate of each test drug administration group was obtained. The results are shown in Table 1.
  • the test drug was administered to 4 rats per group according to the following group structure.
  • Group A Toki dried extract (manufactured by Ogi Pharmaceutical Co., Ltd.) was dissolved in physiological saline and administered at a dose of 25 mg (100 mg in terms of bulk drug substance) / kg body weight.
  • Group B Ekokogi dry extract (manufactured by Nippon Powder Pharmaceutical Co., Ltd.) and Ogi dry extract (manufactured by Nippon Powder Pharmaceutical Co., Ltd.) are dissolved in physiological saline, and 12 mg (300 mg in terms of bulk drug substance) / kg body weight and 30 mg respectively It was administered at a dose of 240 mg) / kg body weight in terms of bulk drug substance.
  • Group C Toki dried extract (manufactured by Koshiro Pharmaceutical Co., Ltd.), Ezokogi dried extract (manufactured by Nippon Powdery Chemical Co., Ltd.) and dried ogi extract (manufactured by Nippon Powdery Chemical Co., Ltd.) are dissolved in physiological saline and each 25 mg (raw drug substance) The doses were 100 mg) / kg body weight, 14 mg (350 mg bulk drug equivalent) / kg body weight, and 30 mg (240 mg bulk drug equivalent) / kg body weight.
  • the relative value of the increase in blood flow with respect to the control was 1.13 in the single administration group of the extract of Toki, and 1.65 in the administration group of the extract of Ekogi and Ogi, whereas the value of the extract of Toki, Ezocogi and Ogi was It was 1.95 in the combined administration group, and it was speculated that the combination of the extract of Toki and the extract of Ezocogi and Ogi had a synergistic effect on the blood flow increasing action. From the above test results, it became clear that the combination of Toki or its extract, Ezokogi or its extract, or Ogi or its extract exhibits a synergistically enhanced superior blood flow promoting action.
  • Group C Toki dried extract (manufactured by Ogi Pharmaceutical Co., Ltd.) and oxoamidin powder (manufactured by Riken Chemical Industry Co., Ltd.) were dissolved in physiological saline, and 25 mg (100 mg in terms of drug substance) / kg body weight and 50 mg / kg body weight, respectively. The dose was administered. The results are shown in Table 2.
  • mice fasted overnight were allowed to swim for 40 minutes in the same water tank, and then 0.5% methylcellulose aqueous solution (control) or test drug was orally administered.
  • the amount of swimming was evaluated by the number of movements to the adjacent and diagonal areas when the water surface of the aquarium was divided into four.
  • the test drug was administered to 8 mice per group according to the following group structure.
  • Group A Dissolve and suspend Ezokogi dry extract (manufactured by Nippon Powder Chemical Co., Ltd.), Ogi dry extract (manufactured by Nippon Powder Chemical Co., Ltd.), and oxoamidin powder (manufactured by Riken Chemical Industry Co., Ltd.) in 0.5% methylcellulose aqueous solution.
  • Each dose was 36 mg (900 mg in terms of bulk drug substance) / kg body weight, 90 mg (720 mg in terms of bulk drug substance) / kg body weight and 150 mg / kg body weight.
  • Group B Touki dry extract (manufactured by Ogi Pharmaceutical Co., Ltd.), Ekokogi dry extract (manufactured by Nippon Powder Chemical Co., Ltd.), Ogi dry extract (manufactured by Nippon Powder Chemical Co., Ltd.), and oxoamidin powder (manufactured by Riken Chemical Industry Co., Ltd.) Dissolved and suspended in 0.5% methylcellulose aqueous solution, 75 mg (300 mg in terms of bulk drug substance) / kg body weight, 42 mg (1.05 g in bulk drug substance equivalent) / kg body weight, 90 mg (720 mg in bulk drug substance equivalent) / Kg body weight and 150 mg / kg body weight.
  • a 600 mg tablet containing the following components in a daily dose (1 tablet) was produced by a conventional method.
  • the present invention it is possible to provide a medicine that exhibits an excellent blood flow promoting action and fatigue recovery action, and can be used in the pharmaceutical industry, the quasi-drug industry, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention fournit un nouveau médicament possédant une action de rétablissement vis-à-vis de la fatigue. Plus précisément, l'invention concerne un médicament destiné au rétablissement vis-à-vis de la fatigue, et combinant les composants (A) à (C) suivants : (A) une angelica sylvestris chinensis ou un extrait de celle-ci ; (B) un éleuthérocoque ou un extrait de celui-ci ; et (C) une racine d'astragale ou un extrait de celle-ci.
PCT/JP2013/084803 2012-12-26 2013-12-26 Médicament WO2014104162A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014554528A JPWO2014104162A1 (ja) 2012-12-26 2013-12-26 医薬

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2012-283040 2012-12-26
JP2012283040 2012-12-26
JP2013052651 2013-03-15
JP2013-052651 2013-03-15
JP2013081893 2013-04-10
JP2013-081893 2013-04-10

Publications (1)

Publication Number Publication Date
WO2014104162A1 true WO2014104162A1 (fr) 2014-07-03

Family

ID=51021238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/084803 WO2014104162A1 (fr) 2012-12-26 2013-12-26 Médicament

Country Status (2)

Country Link
JP (1) JPWO2014104162A1 (fr)
WO (1) WO2014104162A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5692216A (en) * 1979-12-27 1981-07-25 Sunstar Inc Peripheral circulation improver containing crude drug
JPH06172196A (ja) * 1992-12-04 1994-06-21 Pola Chem Ind Inc 血液粘性低下剤及びそれを含む組成物
JPH10298093A (ja) * 1997-04-24 1998-11-10 Chugai Pharmaceut Co Ltd 内用液剤
WO2008001494A1 (fr) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Agent pharmaceutique destiné à la prévention de la fatigue et/ou à la récupération en cas de fatigue
JP2011052005A (ja) * 2003-04-29 2011-03-17 Limin Pharmaceutical Factory Of Livzon Pharmaceutical Group 党参および黄耆の組成物、それらの調製方法およびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5692216A (en) * 1979-12-27 1981-07-25 Sunstar Inc Peripheral circulation improver containing crude drug
JPH06172196A (ja) * 1992-12-04 1994-06-21 Pola Chem Ind Inc 血液粘性低下剤及びそれを含む組成物
JPH10298093A (ja) * 1997-04-24 1998-11-10 Chugai Pharmaceut Co Ltd 内用液剤
JP2011052005A (ja) * 2003-04-29 2011-03-17 Limin Pharmaceutical Factory Of Livzon Pharmaceutical Group 党参および黄耆の組成物、それらの調製方法およびその使用
WO2008001494A1 (fr) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Agent pharmaceutique destiné à la prévention de la fatigue et/ou à la récupération en cas de fatigue

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BORDIA T ET AL.: "An evaluation of garlic and onion as antithrombotic agents", PROSTAGLANDINS LEUKOT ESSENT FATTY ACIDS, vol. 54, no. 3, 1996, pages 183 - 186 *
KOZO FUKUDA ET AL.: "Toki no Ketsueki Rheology Kojo Sayo ni Kansuru Kenkyu", THE JAPANESE SOCIETY OF PHARMACOGNOSY NENKAI KOEN YOSHISHU, vol. 56TH, 15 September 2009 (2009-09-15), pages 92 *
PIERRE S ET AL.: "Inhibitory effect of aqueous extracts of some herbs on human platelet aggregation in vitro", PLATELETS, vol. 16, no. 8, 2005, pages 469 - 473 *
SOBENIN I ET AL.: "Anti-aggregatory and fibrinolytic effects of time-released garlic powder tablets", MEDICAL AND HEALTH SCIENCE JOURNAL, vol. 7, no. 2, June 2012 (2012-06-01), pages 40 - 45 *
TAKAAKI MURATA ET AL.: "Usefulness of the Chinese Medicine 93N-HJ in Fatigue, Lumbago, etc.", CLINICAL REPORT, vol. 29, no. 1, 1995, pages 205 - 213 *
TENPU BUNSHO 'Q & P KOWA GOLD A, October 2011 (2011-10-01) *
YASUNARI IKOSHI ET AL.: "Fuhotokiko' no Tsukaikata", CLINICAL JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 7, no. 1, 1986, pages 62 - 63 *
YOICHI UMETADA ET AL.: "Clinical Evaluation on Short-Term Treatment with K-QL", BASIC PHARMACOLOGY & THERAPEUTICS, vol. 25, no. 12, 1997, pages 2997 - 3002 *

Also Published As

Publication number Publication date
JPWO2014104162A1 (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
CN105919136A (zh) 一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法
CN105832794A (zh) 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用
CN105596646A (zh) 控制血糖及治疗血脂代谢异常的药品、保健品或食品组合物
JP5114399B2 (ja) 疲労予防及び／又は回復のための医薬
CN105287614B (zh) 一种灯银脑通药物组合物及其制备方法、制剂与应用
CN117018125B (zh) 一种用于抗疲劳的药物组合物
JP5961034B2 (ja) 安定化方法
EP3086798A1 (fr) Formulations à base d'astragaloside iv ou d'extraits en contenant pour la prévention et le traitement de l'insomnie et des troubles liés au décalage horaire
CN102188519B (zh) 一种治疗肝纤维化的中药复方制剂及其制备方法
JP6196847B2 (ja) 防已含有組成物
WO2014104162A1 (fr) Médicament
JP2019202970A (ja) 医薬
JP2014214141A (ja) 防已含有組成物
TW201902504A (zh) 南洋山蘇水萃物的用途
JP5114394B2 (ja) 疲労回復のための医薬
CN107753567B (zh) 一种抗疲劳药物组合物及其制备方法及应用
CN104223066A (zh) 一种改善睡眠的中药组合物
CN104225228A (zh) 一种用于调节血糖的中药制剂
JP2014221725A (ja) 防已含有組成物
CN103751692B (zh) 一种海狗鞭特补胶囊及其制备方法
TW201907939A (zh) 南洋山蘇水萃物的用途
JP2022170992A (ja) 生薬等含有液状組成物
CN106389999B (zh) 一种解除醉酒的中药组合物及其应用
CN116568312A (zh) 稳定的半固体可咀嚼凝胶组合物及其制作和使用方法
CN104940256A (zh) 一种降血糖中药制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13866988

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014554528

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13866988

Country of ref document: EP

Kind code of ref document: A1